Tigris device, which is a third generation and self-expanding stent, has been designed to improve anatomical conformability with the natural movement of the knee when treating PAD.
The device features a dual component structure, which is created by using a single-wire nitinol stent with flexible and biocompatible fluoropolymer interconnections.
Gore has designed the stent to withstand biomechanical forces such as extension, compression, flexion and torsion without fractures even in the most complex anatomies, including superficial femoral artery (SFA) and proximal popliteal artery (PPA).
The stent also features CBAS heparin surface that will resist thrombus formation, a problem common in both bare metal and drug-eluting stents.
According to the firm, the vascular stent was found to have zero fractures in the US clinical study, while the control arm devices experienced a 27% fracture rate.
The company received CE mark approval for the Tigris device in 2011.
Gore peripheral interventional business unit leader Ray Swinney said: “At Gore, we pride ourselves in continuous evaluation of how our technologies can benefit patients.
“To design an uncovered stent that navigates and conforms to the complex anatomy of the artery, we leveraged our long history with endovascular devices to develop the Gore Tigris vascular stent.
“The addition of this device to our peripheral interventional portfolio enables physicians to treat more diverse cases with Gore’s best in class products.”
Image: Gore’s Tigris dual-component vascular stent with a fluoropolymer / nitinol design. Photo: courtesy of Business Wire.
